About Us

MABT’s current mission is to develop therapies for advanced Flu and Coronavirus patients.

MABT was founded in 2011 with the mission of eradicating life-threatening infectious diseases using a transformative, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. This revolutionary type of immune system-based therapy is called “immunotherapy”.

We are a pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively creating a revolutionary treatment paradigm for viral diseases, such as advanced Flu and Coronavirus.

The 2019 Novel Coronavirus has brought extreme stress on our global healthcare system and hospitals are overwhelmed. Without an effective treatment, hospitals are filling up and patients are dying. A therapy for Coronavirus is desperately needed.

Coronavirus

Current USA Coronavirus Numbers (Updated Weekly)

8,109,811
Total Cases
2,697,837
Active Cases
5,190,654
Recovered Cases
221,320
Fatal Cases

IMT504 Super Charges your own Immune System

Global Market

Global Anti-Infectives Market

Infectious diseases are one of the leading causes of morbidity and mortality throughout the world. The global market for all infectious diseases is expected to be ~$100 billion dollars by 2022, and is …

Fatality Rates

Rabies represents a unique unmet medical need, for which there is no effective therapy. Rabies is the most lethal organism known to the medical community, with a fatality rate of …

Antibiotic Resistance

Outside the US, over 700,000 deaths are currently attributed to resistant bacteria. However, given recent trends in resistance, these numbers are expected to skyrocket to over 10,000,000 deaths/year by 2050, …